Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04850898 | Study of SAB-176 in Healthy Adult Participants | PHASE2 | COMPLETED | 62 | — | — | Jun 23, 2021 | Oct 8, 2021 | Jan 22, 2025 | 1 | United Kingdom |
Area under the viral load-time curve (VL-AUC) of Influenza A/California/2009 H1N1 virus, as determined by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) on nasal samples.
| Arm | Type | Description |
|---|---|---|
| Normal Saline Placebo Control | PLACEBO_COMPARATOR | Placebo control dosed 1 time via intravenous infusion |
| SAB-176 - 25mg/kg | EXPERIMENTAL | Investigational Medicinal Product dosed 1 time at 25 mg/kg on day 1 via intravenous infusion |
| Name | Type | Description |
|---|---|---|
| SAB-176 | BIOLOGICAL | Treatment of influenza |
| Placebo | OTHER | Placebo Control |
Inclusion Criteria: 1. An informed consent document signed and dated by the participant and the investigator 2. Aged between 18 and 45 years on the day of signing the study specific ICF. 3. In good health with no history, or current evidence, of clinically significant medical conditions, and no cli...